In-depth journalism and analysis of the pharma, biotech, medtech, and consumer health industries.
Search Our WebsiteLupin’s CEO Vinita Gupta and MD Nilesh Gupta outline the company’s innovation agenda, strategy on GLP-1 drugs including fortnightly candidate bofanglutide, plans to get to number one in the domestic market and the legacy of their father in this podcast interview.
Lupin’s CEO Vinita Gupta and MD Nilesh Gupta outline the company’s innovation agenda, strategy on GLP-1 drugs including fortnightly candidate bofanglutide, plans to get to number one in the domestic market and the legacy of their father in this podcast interview.
Pink Sheet reporter and editors discuss the likely impacts of Center for Drug Evaluation and Research Director Richard Pazdur’s retirement from the FDA and Tracy Beth Høeg becoming the center’s acting director.
Also, Latest News From Europe, Canada, Saudi Arabia, Finland, China, And The US
Also, Latest News From Europe, Canada, Saudi Arabia, Finland, China, And The US
Curve Biosciences has developed a "Whole-Body Intelligence" platform using cfDNA from blood to monitor chronic diseases, starting with the liver. Focused on liver cirrhosis and MASH, the company aims to aid in treatment decisions and plans to expand into monitoring other organs.
Lupin’s CEO Vinita Gupta and MD Nilesh Gupta outline the company’s innovation agenda, strategy on GLP-1 drugs including fortnightly candidate bofanglutide, plans to get to number one in the domestic market and the legacy of their father in this podcast interview.
Pink Sheet reporter and editors discuss the likely impacts of Center for Drug Evaluation and Research Director Richard Pazdur’s retirement from the FDA and Tracy Beth Høeg becoming the center’s acting director.
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
A comprehensive and dependable information source aimed at ensuring industry leaders can stay on top of the latest regulatory, legal, market and commercial developments to anticipate potential threats and identify new opportunities.
Essential updates and comprehensive coverage of industry regulations and emerging policy trends.
In-depth analysis of the global biopharma industry, offering news that goes beyond the headlines.
Exclusive interviews, expert opinion, and critical insights tailored for life science decision-makers.
Contextualized reporting on medtech advancements, market dynamics, industry data, and expert insights.
Unrivalled news and analysis of the global generic, biosimilars and value-added medicines industries.
Your primary source for impactful news and insights in the health, beauty, and wellness industries.
A comprehensive and dependable information source aimed at ensuring industry leaders can stay on top of the latest regulatory, legal, market and commercial developments to anticipate potential threats and identify new opportunities.
Analysis and opinion covers key topic areas such as:
400
Articles
50
Podcasts
100
Analysis
20
Conference Coverage
Sign up today and
see for yourself how we can help.
Karen Coleman
Executive Director,
News and Insights
Ian Haydock
Editor-in-Chief,
APAC
Nielsen Hobbs
Interim Editor-in-Chief,
Pink Sheet
Eleanor Malone
Editor-in-Chief,
Commercial Insights
Ryan Nelson
Editor-in-Chief,
HBW Insight, Medtech Insight
Reach out to emailaddress@emailaddress.com
